Innovent registers Phase II gout trial for IBI3011, Phase I hypertension study for IBI3016
Innovent Biologics posted two new registry entries this week covering an anti-IL-RAP antibody in acute gouty arthritis and a hypertension candidate in Japanese participants.
Innovent Biologics filed two new clinical trial registrations this week, both sponsored by Innovent Biologics (Suzhou) Co. Ltd.
- IBI3011, described as a recombinant Anti-IL-RAP humanized monoclonal antibody injection1, is entering a Phase II trial in acute gouty arthritis. The study is not yet recruiting, with an estimated enrollment of 132 participants1, and the primary outcome is the change in gout pain intensity in the target joint measured by VAS1.
- IBI3016 is being tested in a Phase I study evaluating safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of a single subcutaneous dose of IBI3016 in Japanese participants with mild to moderate hypertension2. The trial is recruiting, with an estimated enrollment of 30 participants2, at 1 site in 1 country: Japan2.
Fact check notes
- Imprecise
Innovent Biologics posted two new registry entries this week
Both trials were first posted within a day of each other, consistent with 'this week', but the sources do not explicitly state a weekly framing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.